Revelation Pharma Corporation Announces Shawn Hodges as CEO.
Founders Jake Beckel and Richard Case to Lead Acquisitions.
TAMPA, Fla., – Osceola Capital (“Osceola”), a lower middle-market private equity firm, announced an update to the Revelation Pharma Corporation (“Revelation”) executive team to accommodate the rapid onboarding of compounding pharmacies across the US. In less than two years, Revelation is now a market leader in the compounding industry. The timing is ideal to bring focus to operations while continuing to aggressively pursue additional acquisitions in this market. The new leadership roles are:
M&A focus: Jake Beckel and Richard Case, the founders of Revelation, and who will remain on the board of directors, will solely focus on helping new companies that wish to join Revelation. Jake and Rich’s team will help pharmacies understand their accurate valuation and support those interested pharmacies through the due diligence process and onboarding into the Revelation network. Richard Case, a healthcare M&A industry veteran, has significant in the acquisitions of healthcare businesses that operate in highly regulated industries. Serving as Chairman of the Board, Jake Beckel, a pharmacist, has deep experience in the compounding space. He most recently served as founder and CEO of AnazaoHealth Corporation, a leading compounding pharmacy that successfully completed 13 acquisitions and ultimately was acquired by Fagron, the world’s largest publicly traded compounding company. “We’re elated that we’re already in the position to adjust our leadership roles to achieve our shared vision in elevating the profession,” said Richard. “Jake and I are excited to focus on M&A activity with sellers to build the premier company in the industry.” Jake added, “Shawn has brought a wealth of industry experience and excellent strategic and leadership skills to Revelation as our new Chief Executive Officer. The Board believes he is a great fit for Revelation, with the combination of skills and experience to lead the business through its next strategic phase.”
Operations/Integration Focus: Revelation’s new CEO is Shawn Hodges, PharmD. With more than 25 years compounding pharmacy experience, Shawn owned and operated Innovation Compounding, that dispensed prescription medications across 49 states. He also served in leadership roles for the pharmacy compounding trade organization, the Alliance for Pharmacy Compounding. Shawn, who rolled a significant portion of his ownership in Innovation into Revelation stock, will continue to build a leadership team that can successfully and fully integrate compounding pharmacies, including operational support, HR, IT, sales and marketing, and compliance. “This is an exciting time for Revelation,” said Shawn. “We are witnessing the vision and concepts created less than two years ago transform into a fast-expanding company. With our management restructure we can further support all the stakeholders that Revelation serves; pharmacies who are interested in selling, our current network of pharmacies, medical experts, but also, most importantly, the patient.”
Ben Moe, Managing Partner at Osceola Capital Management added, “A great deal of momentum has been created in Revelation’s relatively short existence. This is a wonderful opportunity in which the company can place additional leaders in a position to continue to build a national network of compounding pharmacies.”
Other key members of the executive team will remain in leadership roles. Mitchell Bell is the Senior Vice President of 503A Pharmacies and was previously the Vice President of Operations at Innovation Compounding. Will Skinner is the Chief Financial Officer who has specialized in start-ups, alternative investment companies, and healthcare organizations. Jon Pritchett, former Pharmacy Program Director at Accreditation Commission for Health Care (ACHC), now serves as the Vice President of Quality Assurance and Regulatory Affairs.
About Osceola Capital Management
Osceola Capital is a Tampa-based private equity firm that invests in lower middle-market services companies, typically with EBITDA of $2 million to $10 million. Osceola has extensive experience partnering with management teams to execute buy-and-build strategies and drive long-term value creation. The Revelation Strategy Team includes Ben Moe, and Patrick Watkins. To learn more, visit www.osceola.com.
About Revelation Pharma Corporation
Revelation Pharma is a national network of 503A and 503B compounding pharmacies providing innovative and quality pharmaceutical products and services through “industry best” patient care and solutions for customers. Compounding pharmacy will drastically change in the next five years. Revelation believes that compounding pharmacies will need help and support to adjust to these changes in order to continue to serve the needs of the patient and their healthcare provider.
Director of Marketing Communications